News | August 08, 2024
JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
Expect the international business including CDMO business to pick-up in the second half of the financial year
Expect the international business including CDMO business to pick-up in the second half of the financial year
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Strong topline growth driven by solid performance across key brands.
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Subscribe To Our Newsletter & Stay Updated
